Active Biotech announced it has regained global development and commercialization rights over laquinimod, its investigational oral therapy for multiple sclerosis (MS), from Teva Pharmaceuticals. Teva released rights to laquinimod ... Read more
Sweden’s Active Biotech said its experimental therapy Laquinimod failed to meet the primary and secondary objectives of Phase 2 clinical trial evaluating the drug’s potential to treat primary progressive multiple sclerosis.
Laquinimod, also known as Nerventra or ABR-215062, ... Read more
Laquinimod failed to meet its primary Phase 3 clinical trial objective of slowing the progression of relapsing-remitting multiple sclerosis (RRMS) after three months, according to its developers, Teva Pharmaceutical Industries and Active ... Read more
Active Biotech acknowledged in an update on laquinimod, the oral small molecule being developed by Teva Pharmaceutical Industries to treat multiple sclerosis (MS) and Huntington’s disease (HD), that the U.S. Food and Drug ... Read more
Teva Pharmaceutical Industries Ltd. and Active Biotech have discontinued the use of higher doses of the drug laquinimod in two ongoing multiple sclerosis (MS) studies. The decision was based ... Read more
Drug manufacturers Teva Pharmaceutical Industries Ltd. and Active Biotech announced that they expanding the ongoing clinical research program for the study of laquinimod, a potential treatment for primary progressive multiple sclerosis (PPMS), ... Read more
Pin It on Pinterest